Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$56.23 USD
-6.04 (-9.70%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $56.85 +0.62 (1.10%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Viking Therapeutics, Inc. [VKTX]
Reports for Purchase
Showing records 101 - 120 ( 211 total )
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Pivotal Start Imminent for VK2809 NASH Promise
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Recap - VK2809 On Track for 4Q19 Trial Start
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results; Focus Remains on Getting VK2809 Phase 2b NASH Started; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results Prep Time Now for VK-2809 Phase 2b; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Each Passing Moment Delivers Stronger VK2809 Thesis While Shares Under Major Attack; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Efficacy, Safety and Cardiovascular Protection; VK2809 Profile Continues to Impress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Walk Through Yas'' Shoes at EASL - Our EASL Roadmap
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Significant Efficacy Proven at Lower Dose; VK2809 Strengthens its Competitive Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NASH Weekly: Should You Go to EASL With Late Breakers Abstracts Revealed?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2018 Results; Moons Continue to Align for VK2809; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J